Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity

Dagogo-Jack, I; Rooney, M; Lin, JJ; Nagy, RJ; Yeap, BY; Hubbeling, H; Chin, E; Ackil, J; Farago, AF; Hata, AN; Lennerz, JK; Gainor, JF; Lanman, RB; Shaw, AT

Shaw, AT (reprint author), Massachusetts Gen Hosp, 32 Fruit St, Boston, MA 02114 USA.

CLINICAL CANCER RESEARCH, 2019; 25 (22): 6662

Abstract

Purpose: Acquired resistance to next-generation ALK tyrosine kinase inhibitors (TKIs) is often driven by secondary ALK mutations. Here, we investigate......

Full Text Link